Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 161

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 161
---
, joined the Company
as a director on June 2023, and since June 22, 2023, he serves as Chairman. He co-founded several technology companies, including Dien-A
Mollecular Biology Ltd. (2018 -present) , a NGS technology company focused on significant elongation of DNA sequencing reads; Advanced
Concepts in Biology LLC (2018 – present), focused on advanced gene expression technologies; Biotic Therapeutics Ltd. (2021 –
2023), focused on anti-inflammatory polyphenol small molecules research.

Mr. Bartal received B.Sc. in 1990 in biology
from Tel Aviv University and M.A. from Universitat de Barcelona.

Matti Munk, 53 was appointed a director
on February 18, 2021. Mr. Munk has 20 years of experience in international investment and banking; engaging in international activities,
economics, financing, management. Since 2020, he has served as director and Chief Economist at Comforte Capital. Amazon Aggregator; since
2016, he serves as CEO of Western Wall Street, leading corporate finance and Capital Raises for Israeli Corporations and UK real estate
projects and performing oversight/financial reporting on behalf of investors in local the corporations. Between 2008 and 2016, Mr. Munk
served as manager in International Private Banking. Mercantile Discount Bank. Mr. Munk was responsible for overseeing department and
commercial loans division and establishing and maintaining internal and external relationships with Institutional Market and Family offices.
Mr. Munk received MBA in Finance in 2011 from University of Liverpool, UK and BA in Economic and Finance in 1997 from Bar-Ilan University.

Yoram Drucker,59, was appointed
a director as of February 26, 2025. Mr. Drucker is a serial entrepreneur, founding several companies over the last twenty years and focusing
on the Israeli biotech industry. From October 2017 to November 2023, Mr. Drucker founded and served as Vice President of Business Development
for InnoCan Pharma Ltd., a company traded on the Canadian Stock Exchange. From September 2016 to April 2020, Mr. Drucker was the CEO
and Co-founder of a biotech company, ViruCure, developing an oncolytic-virus based technology platform. Prior to this, he served as the
CEO and Executive Chairman of Cell Source Ltd. from 2011 to 2014. Additionally,